Compare · DOMH vs NVO
DOMH vs NVO
Side-by-side comparison of Dominari Holdings Inc. (DOMH) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DOMH and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 3511.4x DOMH ($49.5M).
- Over the past year, DOMH is down 65.2% and NVO is down 28.6% - NVO leads by 36.6 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 1 for DOMH).
- NVO has more recent analyst coverage (25 ratings vs 0 for DOMH).
- Company
- Dominari Holdings Inc.
- Novo Nordisk A/S
- Price
- $1.96-4.39%
- $38.82-1.05%
- Market cap
- $49.5M
- $173.66B
- 1M return
- -20.00%
- -10.14%
- 1Y return
- -65.22%
- -28.57%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 4
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest DOMH
- SEC Form 4 filed by Dominari Holdings Inc.
- Dominari Holdings Announces Up To $5,000,000.00 Share Repurchase Program
- Dominari Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- President Wool Kyle Michael bought $209,190 worth of shares (100,000 units at $2.09), increasing direct ownership by 2% to 4,311,828 units (SEC Form 4)
- CEO Hayes Anthony bought $209,190 worth of shares (100,000 units at $2.09), increasing direct ownership by 2% to 4,600,873 units (SEC Form 4)
- NEW AMERICA ACQUISITION I CORP. ANNOUNCES CHIEF FINANCIAL OFFICER TRANSITION;
- Dominari Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Dominari Year to Date Revenue Increases by 14% Over 2025
- SEC Form 10-Q filed by Dominari Holdings Inc.
- New America Acquisition I Corp. Announces Leadership Transition; Kyle Wool Appointed Chief Executive Officer
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank